Table 4.
Response to the PD-1/PD-L1 inhibitors according to PD-L1 expression in HNSCC clinical trials
| Reference |
ORR for all the patients included with nivo/pembro |
|
For CPS |
|
For TS |
|||
| % of patients with CPS≥1% | Response (%) of patients with CPS≥1% | Response (%) of patients with CPS<1% | % of patients with TS≥1% in group Nivo/pembro | Response (%) of patients with TS≥1% | Response (%) of patients with TS<1% | |||
| Pembrolizumab | ||||||||
| Keynote 012 (Seiwert) | 18 (8/45) | 100% | 18 (8/45) | NEV | ||||
| Keynote 012 (Chow) | 18 (24/132) | 81 (107/132) | 21 (23/107) | 4 (1/25) | 67 (89/132) | 19 (17/89) | 16 (7/43) | |
| Keynote 055 (Bauml) | 17 (28/166) | 84 (140/166) | 18 (25/140) | 12 (3/26) | ||||
| Keynote 040 (Cohen) | 14 (36/247) | 78(387/495) | 17 (34/196) | 4 (2/50) | ||||
| Keynote 048 (Burtness) | 23(31/133) for CPS≥20 19 (49/257) for CPS≥1 | 85 (754/882) | 19(49/257) | NR | ||||
| Nivolumab | ||||||||
| Checkmate 141 NEJM | 13 (32/240) | NR | NR | NR | 55(88/161) | 17 (15/88) | 12.3 (9/73) | |
| Checkmate 141 OO | 13 (32/240) | |||||||
CPS, combined positive score; NEJM, New England Journal of Medicine; Nivo, nivolumab; Pembro, pembrolizumab; TPS, tumor proportion score; NR, not reported; OO, oral oncology.